NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated
Clinical Trials
3 trialsNCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed
NCT00189345 2006-11-08
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
AGO Study Group
Phase 2 Completed